




RealRate

PHARMACEUTICAL 2011

Biomarin Pharmaceutical INC
Rank 16 of 31

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 12% points above the market average of 287%.

Input Variable	Value in 1000 USD
Assets, Current	504,260
Cost of Goods Sold	70,285
Intangible Assets	157,012
Liabilities, Current	83,844
Liabilities, Non-Current	84,001
Other Assets	379,485
Other Compr. Net Income	0
Other Expenses	-196,846
Other Liabilities	377,521
Other Net Income	2,023
Other Revenues	376,267
Property and Equipment	221,866
Research and Development	147,309
Selling, General and Administrative Expense	151,723

Output Variable	Value in 1000 USD
Assets	1,262,623
Liabilities	545,366
Expenses	172,471
Revenues	376,267
Stockholders Equity	717,257
Net Income	205,819
Comprehensive Net Income	205,819
BaseVar	1,179,375
ECR before Limited Liability	196%
Economic Capital Ratio	300%